Order Article Reprints

Muğlu H, Helvacı K, Köylü B, Yücel MH, Celayir ÖM, Demirci U, Uluç BO, Başaran G, Korkmaz T, Selçukbiricik F, et al. The Clinical Outcomes and Safety of Sacituzumab Govitecan in Heavily Pretreated Metastatic Triple-Negative and HR+/HER2− Breast Cancer: A Multicenter Observational Study from Turkey. Cancers. 2025; 17(9):1592. https://doi.org/10.3390/cancers17091592

Muğlu, Harun, Kaan Helvacı, Bahadır Köylü, Mehmet Haluk Yücel, Özde Melisa Celayir, Umut Demirci, Başak Oyan Uluç, Gül Başaran, Taner Korkmaz, Fatih Selçukbiricik, and et al. 2025. "The Clinical Outcomes and Safety of Sacituzumab Govitecan in Heavily Pretreated Metastatic Triple-Negative and HR+/HER2− Breast Cancer: A Multicenter Observational Study from Turkey" Cancers 17, no. 9: 1592. https://doi.org/10.3390/cancers17091592

Muğlu, H., Helvacı, K., Köylü, B., Yücel, M. H., Celayir, Ö. M., Demirci, U., Uluç, B. O., Başaran, G., Korkmaz, T., Selçukbiricik, F., Ölmez, Ö. F., & Bilici, A. (2025). The Clinical Outcomes and Safety of Sacituzumab Govitecan in Heavily Pretreated Metastatic Triple-Negative and HR+/HER2− Breast Cancer: A Multicenter Observational Study from Turkey. Cancers, 17(9), 1592. https://doi.org/10.3390/cancers17091592